Breast Cancer Screening Inequality: Ethnic Minorities Face Delays 2026

Breast cancer screening inequality in England is under the spotlight after new research shows that people from minority ethnic backgrounds are up to a third less likely to be diagnosed with breast cancer through routine screening. The analysis, led by academics at the University of Surrey and funded by Breast Cancer Now, highlights significant disparities in diagnosis pathways that could impact survival rates.

The study examined data from 86,564 adults diagnosed with breast cancer between 2009 and 2019, using the Clinical Practice Research Datalink and the Cancer Registration Tumour and Treatment datasets. It found that people from Black, Asian, and mixed backgrounds, as well as those from deprived backgrounds, were up to 33% less likely to be diagnosed via screening compared to their white, more affluent counterparts.

Key Findings: Disparities in Diagnosis Pathways

The research uncovered a consistent pattern of inequality across the diagnostic journey. People from marginalised groups were not only less likely to be diagnosed through routine screening but also more likely to be diagnosed through urgent suspected cancer referrals (up to 31% more likely) and emergency presentations (up to 37% more likely).

These findings suggest that individuals from these groups may face barriers to accessing screening services, leading to later diagnoses when symptoms become severe enough to require urgent or emergency care. Late diagnosis often means more advanced disease, which can complicate treatment and reduce survival chances.

• Screening uptake gap: People from Black, Asian, and mixed backgrounds are up to 33% less likely to be diagnosed with breast cancer via routine screening.
• Emergency diagnosis: These groups are up to 37% more likely to be diagnosed through emergency presentation, indicating delayed detection.
• Deprivation link: People from deprived backgrounds face similar disadvantages, compounding the inequality.
• Survival impact: Breast Cancer Now warns that these inequalities affect survival rates and must be addressed urgently.

Why These Disparities Matter

Breast cancer screening aims to detect cancer early, when treatment is more effective and survival outcomes are better. When certain groups are less likely to access screening, they miss this opportunity for early detection. Instead, they may wait until symptoms appear and then seek care through urgent or emergency routes, which often means the cancer has progressed.

Manveet Basra, associate director of public health, inclusion and awareness at Breast Cancer Now, emphasized that people from marginalised groups “face inequalities at every stage of their breast cancer experience, and tragically this impacts their survival rates.” This underscores the need for targeted interventions to ensure equitable access to screening and timely diagnosis.

Barriers to Screening Access

While the study did not pinpoint specific causes, previous research suggests multiple barriers may contribute to lower screening uptake among ethnic minorities and deprived populations. These can include language barriers, cultural beliefs, lack of awareness, mistrust of the healthcare system, and practical obstacles such as transportation or taking time off work.

Understanding these barriers is crucial for designing effective strategies to improve screening rates. Breast Cancer Now calls for further research to identify the root causes and to develop interventions that address the unique needs of these communities.

Comparison of Diagnosis Routes by Group

The table below summarizes the key differences in diagnosis pathways between marginalised groups and the general population, based on the study's findings.

What Needs to Change

Addressing these inequalities requires a multifaceted approach. Health authorities must work to improve screening uptake among underrepresented groups through culturally sensitive awareness campaigns, removing practical barriers, and building trust. Healthcare providers should also be vigilant for potential biases in referral pathways.

Breast Cancer Now is calling for action to ensure that everyone, regardless of background, has equal access to early diagnosis and effective treatment. The charity emphasizes that understanding who is less likely to be diagnosed via screening is the first step toward creating targeted interventions.

As Basra noted, knowing what barriers people face can help shape solutions. This research provides a foundation for developing strategies to reduce disparities and improve outcomes for all.

What to Watch Next

Following this analysis, stakeholders will be looking for policy responses and pilot programs aimed at increasing screening participation in underserved communities. Future research should explore the effectiveness of interventions and monitor progress in reducing these gaps.

For individuals, it's important to be aware of screening invitations and to discuss any concerns with healthcare providers. Early detection remains a key factor in successful breast cancer outcomes.

FAQ

These findings add to a growing body of evidence on health inequalities in England. Similar disparities have been documented in other screening programs, such as cervical screening, where initiatives like the NHS cervical screening bus have been introduced to boost access in underserved communities. You can read about that effort in this article on NHS cervical screening bus boosts cancer test access.

Inequalities also extend to other areas of cancer diagnosis and care. For instance, research has shown that breast cancer screening guidelines may discriminate against families with certain genetic risks. This raises important questions about how we ensure equity in screening for all. Our analysis of breast cancer screening guidelines discriminate against families explores this issue further.

In addition, emerging technologies like AI are being explored to improve cancer detection and reduce disparities. A recent study found that AI mammogram screening can detect heart disease in women, potentially offering a dual benefit. You can learn more about this development in our article on AI mammogram screening detects heart disease in women.

While this research focuses on breast cancer, similar principles apply to newborn screening programs, where early detection can be life-saving. For example, the recent expansion of newborn screening for spinal muscular atrophy (SMA) in England is a landmark move. We discuss this in detail in our post on newborn SMA screening in England: a landmark health move.

However, some experts argue that other rare diseases, such as Duchenne muscular dystrophy (DMD), deserve equal attention in newborn screening. This is a complex ethical and practical debate. You can explore the arguments in our articles on newborn screening for SMA: why DMD deserves equal attention and newborn screening for SMA: why Duchenne MD deserves inclusion.

Finally, public perceptions of health risks can influence screening behaviors. A recent study found that the public overestimates the risk of certain diseases among minority ethnic groups, which could contribute to stigma or misperceptions. Our report on public overestimates minority ethnic killers in England and Wales sheds light on this issue.